These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 11038028)

  • 21. Relevance of intraocular involvement in the management of primary central nervous system lymphomas.
    Ferreri AJ; Blay JY; Reni M; Pasini F; Gubkin A; Tirelli U; Calderoni A; Zucca E; Cortelazzo S; Chassagne C; Tinguely M; Borisch B; Berger F; Ponzoni M; Cavalli F;
    Ann Oncol; 2002 Apr; 13(4):531-8. PubMed ID: 12056702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
    Correa DD; Shi W; Abrey LE; Deangelis LM; Omuro AM; Deutsch MB; Thaler HT
    Neuro Oncol; 2012 Jan; 14(1):101-8. PubMed ID: 22013168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
    Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined modality therapy for primary CNS lymphoma.
    DeAngelis LM; Yahalom J; Thaler HT; Kher U
    J Clin Oncol; 1992 Apr; 10(4):635-43. PubMed ID: 1548527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary individual adjuvant chemotherapy for primary central nervous system lymphomas based on the expression of drug-resistance genes.
    Kunishio K; Okada M; Matsumoto Y; Nagao S
    Brain Tumor Pathol; 2004; 21(2):57-61. PubMed ID: 15700834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.
    Ferreri AJ; Licata G; Foppoli M; Corazzelli G; Zucca E; Stelitano C; Zaja F; Fava S; Paolini R; Franzin A; Politi LS; Ponzoni M; Reni M
    Oncologist; 2011; 16(3):336-41. PubMed ID: 21346023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary central nervous system lymphoma: is there still a role for radiotherapy?
    Graber JJ; Omuro A
    Curr Opin Neurol; 2011 Dec; 24(6):633-40. PubMed ID: 21968551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose methotrexate for elderly patients with primary CNS lymphoma.
    Zhu JJ; Gerstner ER; Engler DA; Mrugala MM; Nugent W; Nierenberg K; Hochberg FH; Betensky RA; Batchelor TT
    Neuro Oncol; 2009 Apr; 11(2):211-5. PubMed ID: 18757775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute].
    Usui N; Dobashi N; Yano S; Yahagi Y; Takei Y; Otsubo H; Takahara S; Yamaguchi Y; Saito T; Minami J; Kamiyama Y; Morikawa N; Machishima T; Osawa H; Aiba K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1277-82. PubMed ID: 20647709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
    Omuro AM; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2005 Jan; 64(1):69-74. PubMed ID: 15642906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
    DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
    J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
    Han X; Ji Y; Ouyang M; Zhu T; Zhou D
    Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis.
    Prica A; Chan K; Cheung MC
    Br J Haematol; 2012 Sep; 158(5):600-7. PubMed ID: 22734565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
    J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.